Pharmaceutical Executive-03-01-2020

Exploring the challenge for pharma in adapting multichannel marketing strategies for the global stage, while trying to refine messages and communicate a brand identity to multiple local audiences.

Examining the key learnings from BCG’s 2019 benchmark study-and the capabilities uncovered that will be critical to future performance.

Amid concerns over a potential 'wild west' climate for data analytics in pharma, taking a long-term, proactive, and enterprise view of your company’s data may be the best way to keep your organization and reputation safe.

How to capitalize on the rise of omnichannel engagement in pharma and pursue myriad modes of message delivery in today’s digital world.

Initiatives aim to limit the gamesmanship that can inhibit prescribing of follow-on biologics.

The collection of source plasma for new therapies igniting debate.

A look at the ongoing barriers and opportunities in building connections between HCPs, patients, and pharma through social media.

AstraZeneca’s Habib Bennaceur talks about the key transitions in his career-from local to global-and his current role in positioning AZ’s Farxiga as a drug with the potential to impact the lives of both patients with and without type 2 diabetes.

Approach for pharma field sales reps in need of reboot.

Click the title above to open the Pharmaceutical Executive March 2020 issue in an interactive PDF format.

With an estimated annual growth rate of 10%, the Middle East is now consistently outpacing traditionally sought-after “pharmerging” heavyweights such as China and Brazil. The United Arab Emirates is at the center of this newfound momentum-asserting its own credentials as a prospective destination for big-ticket foreign investment in healthcare.